Thomas Decker
Overview
Explore the profile of Thomas Decker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
231
Citations
9699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karjalainen A, Witalisz-Siepracka A, Prchal-Murphy M, Martin D, Sternberg F, Krunic M, et al.
Cell Mol Life Sci
. 2025 Mar;
82(1):98.
PMID: 40025196
Tyrosine kinase 2 (TYK2) deficiency and loss or inhibition of kinase activity in men and mice leads to similar immune compromised phenotypes, predominantly through impairment of interferon (IFN) and interleukin...
2.
Stintzing S, Klein-Scory S, Fischer von Weikersthal L, Fuchs M, Kaiser F, Heinrich K, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401174.
PMID: 39903881
Purpose: The FIRE-4 study randomly assigned patients with first-line wild-type (wt) metastatic colorectal cancer to either flourouracil (FU), folinic acid, and irinotecan (FOLFIRI) plus cetuximab until progression or intolerable toxicity...
3.
Hart L, Im S, Tolaney S, Campone M, Pluard T, Sousa B, et al.
Eur J Cancer
. 2025 Jan;
217:115225.
PMID: 39826197
Background: Ribociclib + endocrine therapy (ET) showed significant progression-free survival (PFS) and overall survival (OS) benefits in the MONALEESA trials in patients with HR+ /HER2 - advanced breast cancer (ABC)....
4.
Thill M, Zahn M, Welt A, Nusch A, Zaiss M, Engelken K, et al.
Int J Cancer
. 2024 Dec;
156(9):1770-1782.
PMID: 39707595
Cyclin-dependent kinase 4/6 inhibitors (CDKIs) in combination with endocrine therapy (ET) are the standard-of-care in the first-line treatment of HR-positive, HER2-negative metastatic breast cancer. In the absence of direct head-to-head...
5.
Zimmer P, Esser T, Lueftner D, Schuetz F, Baumann F, Rody A, et al.
BMC Med
. 2024 Oct;
22(1):442.
PMID: 39379960
Background: Increased levels of physical activity are associated with a reduction of breast cancer mortality, especially in postmenopausal women with positive hormone receptor status. So far, previous observational case-control and...
6.
Babadei O, Strobl B, Muller M, Decker T
J Biol Chem
. 2024 Sep;
300(10):107771.
PMID: 39276937
Interferon-induced genes are among the best-studied groups of coregulated genes. Nevertheless, intense research into their regulation, supported by new technologies, is continuing to provide insights into their many layers of...
7.
Fortelny N, Farlik M, Fife V, Gorki A, Lassnig C, Maurer B, et al.
Nat Immunol
. 2024 Apr;
25(5):847-859.
PMID: 38658806
Immune cells need to sustain a state of constant alertness over a lifetime. Yet, little is known about the regulatory processes that control the fluent and fragile balance that is...
8.
Ravi Sundar Jose Geetha A, Fischer K, Babadei O, Smesnik G, Vogt A, Platanitis E, et al.
EMBO J
. 2024 Apr;
43(11):2233-2263.
PMID: 38658796
Type I interferons (IFN-I, including IFNβ) and IFNγ produce overlapping, yet clearly distinct immunological activities. Recent data show that the distinctness of global transcriptional responses to the two IFN types...
9.
Luftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, et al.
Int J Cancer
. 2024 Mar;
155(1):128-138.
PMID: 38447007
BRAWO, a real-world study, assessed the efficacy, quality of life (QoL) and safety of EVE + EXE in postmenopausal women with HR+/HER2- advanced breast cancer (ABC) in routine clinical practice....
10.
Decker T, Zaiss M, Klein D, Hahn A, Hagen V, La Rosee P, et al.
Breast Care (Basel)
. 2024 Feb;
19(1):49-61.
PMID: 38384487
Background: We investigated the efficacy and health-related quality of life (HRQoL) in patients receiving either ribociclib plus endocrine therapy (ET) or chemotherapy with/without bevacizumab as first-line treatment of metastatic hormone...